###### Strengths and limitations of this study

-   To our knowledge, this is the first study to describe the outcome of cardiogenic shock complicating STEMI in Malaysia.

-   The analysis was done on a large data consisting 16 517 patients from 18 hospitals across Malaysia. Hence, it is so far the most representative of Malaysian population in general.

-   Patients were from multi-racial background representing the major racial groups in Asia, that is, Chinese, Indian and Malay.

-   Confounding factors and inter-centre variations in terms of treatment and outcome from this retrospective study cannot be eliminated.

-   This study focuses on in-hospital mortality only. The long-term outcome was not analysed due to insufficient follow-up data.

Introduction {#s1}
============

Cardiogenic shock (CS) is an important cause of death in acute ST-elevation myocardial infarction (STEMI).[@R1] Left ventricular dysfunction is the most common underlying aetiology in CS accounting for about 74.5% of cases.[@R4] There is correlation with the severity of coronary artery disease whereby CS is strongly associated with triple vessel or left main stem coronary involvement[@R6]

Despite the advancement in reperfusion therapy with invasive percutaneous coronary intervention (PCI), the mortality rate remains high. The in-hospital mortality rate even after successful PCI is reported to be as high as 40%.[@R7] Although the incidence of CS complicating myocardial infarctions (MIs) is only around 4%--10%,[@R1] it remains a big challenge in terms of clinical management.

Due to various limitations locally, the rate of coronary reperfusion with primary PCI in STEMI is only about 7% in Malaysia.[@R11] Given the restriction in delivering the preferred revascularisation therapy (primary PCI), the outcome of CS complicating MIs in our population has yet been fully described and no comparison ever made with other studies. Hence, we use data from the Malaysian National Cardiovascular Database-acute coronary syndrome 2006--2013 (NCVD-ACS 2006--2013) to investigate the characteristics and outcome of CS complicating STEMIs in Malaysia.

Methods {#s2}
=======

Patient population {#s2a}
------------------

A total of 16 517 patients diagnosed with STEMI were identified from the Malaysian NCVD-ACS from year 2006 to 2013. The NCVD is a national registry involving 18 hospitals nationally. It captures clinical data on all patients admitted with acute coronary syndromes. The Ministry of Health Malaysia and the National Heart Association of Malaysia (NHAM) sponsor the registry. Data are collected on admission and throughout the patient stay using a standardised case reporting form. A unique national identification number is given to each patient to avoid duplication. Parameters recorded include baseline characteristics and clinical presentation, in-hospital treatment, procedural details and clinical outcome.

STEMI is defined as a persistent ST-segment elevation of ≥1 mm in two contiguous electrocardiographic leads or the presence of a new left bundle branch block in the setting of positive cardiac markers and/or typical cardiac pain. Patients were divided into two groups based on their Killip class on presentation. Those in Killip class IV were grouped under 'CS' (n=1753) while those in Killip classes I, II and III were grouped under 'non-CS' (n=14 764). The two groups were compared in terms of clinical characteristics, in-hospital invasive treatment, pharmacotherapy and all cause in-hospital mortality. A cross-check with the national death registry was also done to verify the patients' mortality status.

The results of the study will be made public in NHAM website through the NCVD annual reports in interest for the view of the participants. In this study, we use retrospective cohort studies looking at data that have already been existing.

Definition of Killip class {#s2b}
--------------------------

Killip class IV is defined as the presence of hypotension with a systolic blood pressure (BP) lower than 90 mm Hg and evidence of peripheral vasoconstriction. Below are the definitions of the other Killip classes:

Killip I: No clinical signs of heart failure.

Killip II: Presence of rales or crepitation in the lungs bases only or a third heart sound (S3).

Killip III: Presence of frank acute pulmonary oedema.

Killip IV: CS or hypotension (measured as systolic BP \<90 mm Hg), and evidence of peripheral vasoconstriction.

Statictical analysis {#s2c}
--------------------

Categorical variables were described as numbers and percentages. The differences were analysed by χ^2^ test or Fisher exact test. Continuous variables were expressed as median and differences were analysed using t-test. To avert biases in the estimates and loss of power, missing data for explanatory variables were assumed to be missing at random. A generalised linear model with a log link, binomial distribution and a robust variance estimator was used to estimate the risk ratios. The risk ratios represent the relative risk for mortality of the non-CS group compared with the CS group. Subsequently, risk ratios of CS patients with PCI done and without PCI were also compared. Variables that were statistically significantly different (a two-sided p value of less than 0.05) between the CS and non-CS patients, that were of clinical importance, and that had sufficient outcomes in the respective subcategories were adjusted for. Finally, binary logistics regression was executed to determine the independent predictors of in-hospital mortality among CS patients. All analyses were conducted using SPSS V.21 statistical software.

Patient and public involvement {#s2d}
------------------------------

There is no patient or public involvement in the development of this study's research question and outcome. All data were obtained retrospectively from the Malaysian NCVD-ACS.

Results {#s3}
=======

[Table 1](#T1){ref-type="table"} illustrates the comparison in baseline characteristics between the CS and non-CS group. A total of 1753 out of 16 517 patients (10.6%) presented with CS. Demographically, the CS group contained more patients over the age of 65 (28.6% vs 22.6% p\<0.001). Females and Malay ethnic groups were also seen to be significantly more prevalent in the CS group. In terms of cardiovascular risk factors, they had higher rate of diabetes and hypertension but unexpectedly lower rate of smoking, hyperlipidaemia and premature family history. Other related premorbid conditions were unfavourable to the CS group where they had higher rate of previous MI, cerebrovascular, peripheral vascular, chronic kidney and chronic lung diseases.

###### 

Baseline characteristics of patients with ST-elevation myocardial infarction

  ----------------------------------------------------------------------------------------------
                                 CS (Killip IV)\   Non-CS (Killip I--III) (n=14 764)   P value
                                 (n=1753)                                              
  ------------------------------ ----------------- ----------------------------------- ---------
  Age                                                                                  

   64 years or less              1214 (71.4%)      11 141 (77.4%)                      \<0.001

   \>65 years                    486 (28.6%)       3252 (22.6%)                        

  Gender                                                                               

   Male                          1455 (83.0%)      12 687 (85.9%)                      0.001

   Female                        298 (17.0%)       2077 (14.1%)                        

  Ethnicity                                                                            

   Malay                         1113 (63.5%)      8631 (58.5%)                        0.001

   Chinese                       285 (16.3%)       2632 (17.8%)                        

   Indian                        247 (14.1%)       2466 (16.7%)                        

   Others                        108 (6.2%)        1035 (7.0%)                         

  Risk factors                                                                         

   Smoking (active/ex)           1109 (67.4%)      10 020 (70.0%)                      0.028

   Diabetes                      732 (51.3%)       5257 (42.3%)                        \<0.001

   Hypertension                  891 (61.3%)       7270 (57.2%)                        0.002

   Hyperlipidaemia               372 (32.1%)       3754 (35.3%)                        0.030

   Family history                158 (9.0%)        1658 (11.2%)                        \<0.001

  Premorbids                                                                           

   Cerebrovascular               49 (3.4%)         386 (3.1%)                          0.422

   Previous MI                   208 (15.1%)       1553 (12.6%)                        0.009

   Peripheral vascular disease   10 (0.7%)         35 (0.3%)                           0.007

   Chronic kidney disease        100 (7.1%)        461 (3.7%)                          \<0.001

   Chronic lung disease          58 (4.1%)         285 (2.3%)                          \<0.001

  Myocardial infarct type                                                              

   Inferior infarct              732 (41.8%)       5310 (36.0%)                        \<0.001

   Anterior infarct              743 (42.4%)       6772 (45.9%)                        0.001

  LVEF mean±SD                   38.7±12.2         46.1±11.1                           0.025
  ----------------------------------------------------------------------------------------------

CS, cardiogenic shock; LVEF, left ventricular ejection fraction; MI, myocardial infarction; non-CS, non-cardiogenic shock.

[Table 2](#T2){ref-type="table"} compares the revascularisation treatment between the two groups. Intravenous thrombolysis remained the main emergency reperfusion therapy for both CS and non-CS patients. Although there was no significant difference of symptom to door times between the two groups, the door to needle time was significantly shorter for CS patients (45 min vs 60 min p\<0.001). The difference in the rate of primary PCIs between the two groups was small (11.7% CS vs 10.0% non-CS). Total rate of in-hospital PCIs (inclusive of primary PCIs) was however significantly higher in CS patients (33.6% vs 29.5% p=0.001). [Table 3](#T3){ref-type="table"} shows the administrative rate of evidence-based pharmacotherapy during the admission, which favoured the non-CS patients across all class of medications especially antihypertensives.

###### 

Coronary reperfusion and revascularisation therapy in STEMI patients who have CS and do not have CS

                                                  CS STEMI          Non-CS STEMI      P value
  ----------------------------------------------- ----------------- ----------------- ---------
  Thrombolysis                                                                        
   Given                                          1216 (71.4%)      10 885 (75.2%)    \<0.001
   Not given---proceeded to primary angioplasty   199 (11.7%)       1451 (10.0%)      
   Not given---missed                             129 (7.6%)        1690 (11.7%)      
   Not given---patient refusal                    4 (0.2%)          49 (0.3%)         
   Not given---contraindicated                    156 (9.2%)        391 (2.7%)        
  In-hospital PCI\*                               537 (33.6%)       4083 (29.5%)      0.001
  Door to needle time for thrombolysis (min)      45.0              60.0              \<0.001
  Symptom to door time (min)                      249.98+/−224.74   239.34+/−215.37   0.074

\*PCI done during index admission that was not primary angioplasty---includes rescue PCI, pharmacoinvasive PCI and early routine PCI.

CS, cardiogenic shock; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.

###### 

In-hospital pharmacotherapy

  ----------------------------------------------------------
  Medications      CS STEMI\      Non-CS STEMI\    P value
                   (n=1753)       (n=14 764)       
  ---------------- -------------- ---------------- ---------
  Aspirin          1024 (75.7%)   12 470 (93.3%)   \<0.001

  ADP-antagonist   632 (67.8%)    8346 (81.4%)     \<0.001

  ACE-I/ARB        529 (30.3%)    8128 (55.8%)     \<0.001

  Beta blocker     659 (51.1%)    9185 (71.5%)     \<0.001

  Statin           957 (70.9%)    12 024 (90.5%)   \<0.001
  ----------------------------------------------------------

ACE-I, ACE converting enzyme inhibitor; ADP, ADP diphosphate; ARB, angiotensin receptor blocker; CS, cardiogenic shock; STEMI, ST-elevation myocardial infarction.

[Table 4](#T4){ref-type="table"} compares the all cause in-hospital mortality rate between patients with CS and non-CS. The mortality rate was different between the two groups (34.1% CS vs 5.6% non-CS, p value \<0.001) After multivariate adjustment of confounding factors, we found that the CS group had 7.14 times higher mortality risk compared with the non-CS group.

###### 

In-hospital and 30 day mortality rates

                          No of patients   Death (%)    Unadjusted risk ratio   Adjusted risk ratio     P value
  ----------------------- ---------------- ------------ ----------------------- ----------------------- ---------
  In-hospital mortality                                                                                 
   CS                     1753             598 (34.1)   6.827 (6.104, 7.954)    7.143 (6.365, 8.017)    \<0.001
   Non-CS                 14 764           821 (5.6)    1                       1                       
  30-Day mortality                                                                                      
   CS                     1753             634 (36.2)   7.587 (7.002, 9.552)    8.863 (7.848, 10.009)   \<0.001
   Non-CS                 14 764           1085 (7.3)   1                       1                       

CS, cardiogenic shock.

Mortality data were obtained from official records from the National Registration Department of Malaysia and cross-referenced to patients, however we were unable to get information for 29 patients (0.017%) in the CS group for undetermined reasons. [Table 5](#T5){ref-type="table"} shows the sub-analyses of in-hospital mortality rates among CS patients. Those who had PCI done during the admission had a lower rate of in-hospital mortality (27.0% vs 38.9%) compared with those who did not. Adjusted mortality risk ratio showed that there was a 40% mortality risk reduction in those with PCI done.

###### 

Comparison of mortality rates between cardiogenic shock with or without PCI

  In-hospital mortality   No of patients   Death (%)    Unadjusted risk ratio   Adjusted risk ratio   P value
  ----------------------- ---------------- ------------ ----------------------- --------------------- ---------
  PCI done                537              145 (27)     0.535 (0.428, 0.670)    0.600 (0.513,0.700)   \<0.001
  PCI not done            1063             414 (38.9)   1                       1                     

PCI, percutaneous coronary intervention.

[Table 6](#T6){ref-type="table"} shows univariate analysis of clinical variables related to mortality in the CS group. All variables that were statistically significant from this table were then grouped into a multivariate logistic regression to determine the independent predictors of in-hospital mortality within the CS group. The result of the multivariate logistic regression is tabulated in [Table 7](#T7){ref-type="table"}. We found that the presence of hypertension, diabetes mellitus, chronic lung and kidney diseases, and age of over 65 carried statistically significantly higher mortality risks and hence they seem to be independent predictors of in-hospital mortality. [Table 8](#T8){ref-type="table"} shows the length of stay between the two groups. Patients with CS have significantly longer duration of inpatient stay compared with non-CS.

###### 

Comparison of clinical factors between survivors and non-survivors of cardiogenic shock

                                Survivors (n=1126)   Non-survivors (n=598)   P value
  ----------------------------- -------------------- ----------------------- ---------
  Age \>65 years                226 (20.8%)          253 (43.1%)             \<0.001
  Diabetes                      429 (47.5%)          295 (58.2%)             \<0.001
  Hypertension                  520 (56.5%)          361 (70.4%)             \<0.001
  Smoking status                                                             
   Active/ex-smokers            607 (67.0%)          219 (48.6%)             \<0.001
   Non-smokers                  299 (33.0%)          232 (51.4%)             
  Dyslipidaemia                 224 (30.3%)          143 (35.3%)             0.083
  Previous MI                   126 (14.0%)          82 (17.8%)              0.061
  Chronic lung disease          25 (2.7%)            32 (6.6%)               0.001
  Cerebrovascular disease       27 (2.9%)            21 (4.4%)               0.161
  Peripheral vascular disease   8 (0.9%)             2 (0.4%)                0.337
  Chronic renal disease         46 (5.0%)            54 (11.2%)              \<0.001

MI, myocardial infarction.

###### 

Logistic regression of predictors for in-hospital mortality in cardiogenic shock

                                P value     Risk ratios   95% CI for EXP(B)   
  ----------------------------- ----------- ------------- ------------------- -----------
  **Age \>65**                  **0.000**   **2.470**\*   **2.073**           **2.944**
  Dyslipidaemia                 0.040       0.828         0.691               0.992
  **Hypertension**              **0.000**   **1.427**\*   **1.180**           **1.726**
  **Diabetes mellitus**         **0.000**   **1.600**\*   **1.343**           **1.907**
  Smoking status                0.000       0.675         0.567               0.804
  Previous MI                   0.175       1.177         0.930               1.490
  **Chronic lung disease**      **0.032**   **1.744**\*   **1.048**           **2.903**
  **Chronic renal disease**     **0.000**   **2.853**\*   **2.079**           **3.915**
  Cerebrovascular disease       0.922       1.023         0.648               1.615
  Peripheral vascular disease   0.256       0.410         0.088               1.909
  Constant                      0.000       0.052                             

The bold fonts indicate the variables that predict in hospital mortality in cardiogenic shock patients.

\*Statistically significant predictors of mortality.

MI, myocardial infarction.

###### 

Length of stay of cardiogenic shock (CS) versus non-CS patients

  Total day stay   Cardiogenic shock   Non-cardiogenic shock   P value
  ---------------- ------------------- ----------------------- ---------
  Mean             8.17 (7.53, 8.82)   5.21 (5.12, 5.29)       0.014
  SD               11.561              5.102                   

Discussion {#s4}
==========

CS is a clinical state where cardiac dysfunction results in inadequate tissue perfusion. CS is characterised by a state of haemodynamic insufficiency that may involve hypotension (systolic blood pressure \<90 mm Hg), significant decrease in mean arterial pressure from baseline and reduced cardiac index. CS can be multifactorial but most commonly occurs secondary to MI.

CS complicating an MI more commonly occurs in ST elevation myocardial infarctions (STEMIs) compared with non-STEMIs and is a predictor of poor prognosis. Data from our NCVD registry showed in-hospital mortality rates of 34.1%. This figure is lower than other MI registries and trials such as the SHOCK trial, which reported in hospital mortality rates of at least 48%. Reasons for the lower figures are unclear, but may be contributed to by a common practice of early hospital discharging of STEMI patients, which may not capture data on patients who died at home early after discharge that would be reflected in 30-day outcomes if these data were available.

Preexisting conditions including hypertension, diabetes mellitus, chronic kidney and lung disease conferred a higher risk of death in our patients, which may reflect poor pre-hospital reserve that is ill prepared to cope with a major stressor such as CS. Increasing age was also a predictor of mortality in our cohort with adults over 65 years of age more than twice more likely to die in hospital if they had CS complicating a STEMI. Age was also found in another study to be the parameter most strongly associated with developing CS after an MI with every 10-year increase in age the risk of developing shock was greater by 47%.[@R12] We observed an interesting finding of significantly lower rates of smoking, family history and dyslipidaemia in the CS group. It is not clear whether this represents under-reporting or under-diagnosis of risk factors or these are paradoxical risk factors for developing CS in STEMI in our population. Nonetheless, further studies would be appropriate to investigate this further, perhaps with future data from NCVD.

Data show that CS patients in the setting of acute MI who were treated non-invasively had poorer outcome and primary PCI is superior to thrombolytic therapy.[@R12] Similar to other registries and studies, our data showed improved survival for patients who underwent in-hospital PCI including primary PCI.[@R12] The adjusted risk of death was reduced by 40% for patients who received PCI during the index admission compared with those who did not. Intravenous thrombolysis remains the most frequent mode of achieving reperfusion in Malaysia due to several factors. PCI in Malaysia is more costly than thrombolysis and primary or urgent PCI services are limited to patients presenting to one of several PCI centres or their network hospitals, which explains why around only 10% of patients received primary PCI. Nonetheless, in the SHOCK trial, thrombolysis was superior to medical therapy only and is recommended in many guidelines as a reperfusion strategy when PCI is not possible or delayed, particularly when patients present within 3 hours of symptoms.[@R17] We did not have any data on intra-aortic balloon pump or assist devices in our patients in this registry. Our data showed a shorter door to needle time in patients presenting with CS compared with non-CS. We postulate several factors---CS patients would be appear more ill during initial assessment and the presence of hypotension would likely push for more urgent and swift diagnostic and management steps. In our personal experience, patients with non-CS STEMI may also present in atypical ways that may delay or make assessment less urgent, hence explain the longer door to needle time. Ideally, we would have included the door to balloon data for comparison, however that data are contained in a separate registry called the NCVD-PCI registry, which we did not have access to.

Efforts are being made to increase coverage of primary PCI through the development of a hub and spoke model for STEMI s called the MySTEMI Network. Non-PCI centres (hub) are paired with a PCI capable centre (spoke) whereby patients presenting to a non-PCI hospital with a STEMI are transferred to a PCI centre for primary PCI.[@R18] We hope that with the rolling out of this MySTEMI Network nationally, we are able to offer PCI as the main reperfusion modality for STEMI patients. Efforts are also being made to improve prescribing rates of evidence-based therapy through clinical audits and CME sessions. There was a low rate of antiplatelet prescription particularly in the CS group, which has been noted in other local studies.[@R11] Although the exact reasons to explain the low prescription rates in our population were not detailed in the NCVD registry, one factor could be the increased bleeding rates in patients with CS.[@R20] We recognise that although our findings are based on the NCVD data, these may not be truly representative of the current situation. The current NCVD is incomplete as there are still several hospitals that are not yet fully contributing towards NCVD data; efforts are however being taken to improve this. Increased reporting will only improve the accuracy of future studies and allow better allocation of resources in improving outcomes.

Conclusion {#s5}
==========

CS complicated STEMI in about 10.6% of our patients. The in-hospital mortality was high (34.1%) and invasive coronary revascularisation lowered the mortality rate substantially. Similar to other studies, multiple comorbidities including increased age were predictors of poor prognosis. Greater effort is needed to improve outcomes and increased effort is being made to improve the rate of primary and in-hospital PCI.
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